Dosage guidance:
Safety: The risk of serious hematologic and neurologic toxicity increases after >2 weeks and >4 weeks of therapy, respectively. When prolonged therapy is required, alternative agents are preferred; if benefits of linezolid outweigh risks and prolonged therapy is used, monitor closely.
General dosing (Ref):
GA <34 weeks:
PNA ≤7 days: Oral, IV: 10 mg/kg/dose every 12 hours.
PNA >7 days: Oral, IV: 10 mg/kg/dose every 8 hours.
GA ≥34 weeks: Oral, IV: 10 mg/kg/dose every 8 hours.
Enterococcus faecium (vancomycin resistant) infection: Note: The manufacturer recommends a duration of 14 to 28 days; however, shorter or longer durations may be appropriate; duration should be individualized based on source and extent of infection, response, etc.
GA <34 weeks:
PNA <7 days: Oral, IV: 10 mg/kg/dose every 12 hours; may be increased to 10 mg/kg/dose every 8 hours if clinical response is inadequate.
PNA ≥7 days: Oral, IV: 10 mg/kg/dose every 8 hours.
GA ≥34 weeks: Oral, IV: 10 mg/kg/dose every 8 hours. Note: Case reports describe the use of higher doses up to 12 to 15 mg/kg/dose every 8 hours to treat vancomycin-resistant enterococcal endocarditis and meningitis/ventriculitis in former premature neonates (n=2; GA: 26 and 35 weeks; age at treatment: Term) (Ref).
Pneumonia: Note: The manufacturer suggests treating for 10 to 14 days; however, optimal duration of therapy is unknown; shorter durations may be appropriate.
GA <34 weeks:
PNA <7 days: Oral, IV: 10 mg/kg/dose every 12 hours; may be increased to 10 mg/kg/dose every 8 hours if clinical response is inadequate.
PNA ≥7 days: Oral, IV: 10 mg/kg/dose every 8 hours.
GA ≥34 weeks: Oral, IV: 10 mg/kg/dose every 8 hours.
Skin and soft tissue infection: Note: The manufacturer recommends treatment for 10 to 14 days; however, treatment duration depends on several factors including likely pathogen and extent of infection; shorter durations may be appropriate.
GA <34 weeks:
PNA <7 days: Oral, IV: 10 mg/kg/dose every 12 hours; may be increased to 10 mg/kg/dose every 8 hours if clinical response is inadequate.
PNA ≥7 days: Oral, IV: 10 mg/kg/dose every 8 hours.
GA ≥34 weeks: Oral, IV: 10 mg/kg/dose every 8 hours.
Dosage guidance:
Safety: The risk of serious hematologic and neurologic toxicity increases after >2 weeks and >4 weeks of therapy, respectively. When prolonged therapy is required, alternative agents are preferred; if benefits of linezolid outweigh risks and prolonged therapy is used, monitor closely.
General dosing (Ref):
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours, maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 600 mg every 12 hours.
Bloodstream infection, resistant gram-positive infection (eg, vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus):
Note: Duration of therapy varies based on various clinical factors including causative pathogen, source of bacteremia, and response (Ref).
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose (Ref).
Children ≥12 years and Adolescents: Oral, IV: 600 mg every 12 hours OR 10 mg/kg/dose every 12 hours; maximum dose: 600 mg/dose (Ref).
Endocarditis; pathogen-directed therapy for vancomycin-resistant Enterococcus faecium:
Note: Dosing is from manufacturer labeling for vancomycin-resistant E. faecium infections; guidelines do not provide specific recommendations due to lack of pediatric data. Infectious Diseases consultation is recommended, and prolonged therapy (>4 to 6 weeks) is required; prolonged use of linezolid may be limited by toxicity (Ref).
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 600 mg every 12 hours.
Enterococcus faecium (vancomycin-resistant) infection: Note: The manufacturer recommends a duration of 14 to 28 days; however, shorter or longer durations may be appropriate; duration should be individualized based on source and extent of infection, response, etc.
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours, maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 600 mg every 12 hours.
Exit-site or tunnel infection, peritoneal dialysis catheter (Ref): Note: Treat exit-site infection for ≥2 weeks (≥3 weeks for S. aureus) and at least 7 days after complete resolution; treat tunnel infection for 2 to 4 weeks.
Infants and Children <5 years: Oral: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose.
Children 5 to <12 years: Oral: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral: 600 mg every 12 hours.
Meningitis, including health care-associated ventriculitis/meningitis (eg, cerebrospinal fluid shunt infection) (alternative agent): Limited data available:
Note: Duration should be individualized based on patient characteristics and response; typical duration is 10 to 14 days; longer durations required for abscess or empyema (Ref).
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose (Ref).
Children ≥12 years and Adolescents: Oral, IV: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg/dose (Ref).
Nontuberculous mycobacterial infection, pulmonary (eg, Mycobacterium abscessus): Limited data available:
Patients with cystic fibrosis (Ref): Note: Use as part of an appropriate combination regimen until patient is culture negative on therapy for ≥1 year; use caution in patients chronically coinfected with methicillin-resistant Staphylococcus aureus (MRSA) due to potential for resistance development. Prolonged use of linezolid may be limited by toxicity; guidelines suggest adding high-dose pyridoxine to reduce risk of cytopenias.
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 10 mg/kg/dose every 12 or 24 hours; maximum dose: 600 mg/dose.
Patients without cystic fibrosis (Ref): Note: Use as part of an appropriate combination regimen until patient is culture negative on therapy for ≥1 year. Prolonged use of linezolid may be limited by toxicity. Dosing in BTS guidelines for infants and children is based on WHO recommendations for drug resistant tuberculosis.
Infants and Children <10 years: Oral, IV: 10 mg/kg/dose every 12 hours; maximum dose: 300 mg/dose.
Children ≥10 years: Oral, IV: 10 mg/kg/dose every 24 hours; maximum dose: 600 mg/dose; doses of 300 mg every 24 hours have also been used.
Adolescents: Oral, IV: 600 mg every 12 or 24 hours; consider reducing to 300 mg every 24 hours if serious adverse effects develop.
Osteoarticular infection, acute (eg, septic [bacterial] arthritis, osteomyelitis]): Limited data available:
Note: Duration should be individualized based on several factors including causative pathogen, response to therapy, and normalization of inflammatory markers. Minimum total duration for septic arthritis is 2 to 3 weeks and for osteomyelitis is 3 to 4 weeks; longer duration commonly necessary, particularly for infections caused by MRSA. Prolonged use of linezolid may be limited by toxicity (Ref).
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose (Ref).
Children ≥12 years and Adolescents: Oral, IV: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg/dose (Ref).
Peritonitis (peritoneal dialysis): Note: Recommended treatment duration is 2 to 3 weeks depending on pathogen (Ref):
Infants and Children <5 years: Oral: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose.
Children 5 to <12 years: Oral: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral: 600 mg every 12 hours.
Pneumonia: Note: The usual duration of therapy for uncomplicated, community-acquired pneumonia is 10 days; however, shorter duration may be effective for more mild disease; complicated infection may require longer treatment (Ref). For nosocomial pneumonia (eg, hospital-acquired, ventilator-associated), optimal duration is unknown; the manufacturer recommends 10 to 14 days of treatment, but shorter durations of 7 days are recommended in adults (Ref).
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 600 mg every 12 hours.
Skin and soft tissue infection:
Uncomplicated: Note: Typical duration is 5 days but may be extended if clinical response is inadequate (Ref).
Infants and Children <5 years: Oral: 10 mg/kg/dose every 8 hours.
Children 5 to 11 years: Oral: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral: 600 mg every 12 hours.
Complicated: Note: Typical duration is 7 to 14 days and should be individualized based on clinical response; for necrotizing infection, continue until further debridement is not necessary and the patient has improved clinically, including being afebrile for ≥48 hours (Ref).
Infants and Children <12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 600 mg every 12 hours.
Tuberculosis, active (drug-resistant); treatment: Limited data available: Note: Use as part of an appropriate combination regimen; duration should be individualized based on extent of disease, rapidity of culture conversion, clinical response, and toxicity; use of linezolid for >6 months is recommended for optimal effectiveness. Monitor closely for hematologic and neurologic toxicity (Ref).
Infants and Children <12 years: Note: Dosing for lower weight ranges is based on pharmacokinetic modeling (Ref).
5 to <10 kg: Oral, IV: 15 mg/kg/dose once daily.
10 to 23 kg: Oral, IV: 12 mg/kg/dose once daily.
>23 kg: Oral, IV: 10 mg/kg/dose once daily; maximum dose: 600 mg/dose.
Children ≥12 years and Adolescents: Oral, IV: 10 mg/kg/dose once daily; maximum dose: 600 mg/dose (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Altered kidney impairment: Infants, Children, and Adolescents: IV, Oral: Any degree of kidney impairment: No adjustment is recommended. In patients with impaired kidney function, the 2 primary metabolites may accumulate and the risk of thrombocytopenia is increased. Monitor closely; dosage adjustment may be necessary, but specific recommendations are not available; utilize therapeutic drug monitoring and monitor efficacy closely (Ref).
Hemodialysis, intermittent: Dialyzable, parent drug and metabolites (~30% to 57% removed via high-flux dialyzer) (Ref).
Infants, Children, and Adolescents: IV, Oral: Administer dose after dialysis session; the risk of thrombocytopenia is increased in patients with impaired kidney function. Monitor closely; dosage adjustment may be necessary, but specific recommendations are not available; utilize therapeutic drug monitoring and monitor efficacy closely (Ref).
Peritoneal dialysis: Infants, Children, and Adolescents: IV, Oral: The risk of thrombocytopenia is increased in patients with impaired kidney function. Specific recommendations are not available; utilize therapeutic drug monitoring and monitor efficacy closely (Ref).
Continuous renal replacement therapy (CRRT): Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Flow rates vary widely in pediatric patients. Appropriate dosing requires consideration of drug penetration to site of infection, minimum inhibitory concentration (MIC) of bacteria, and severity of illness. Close monitoring of response and adverse reactions due to drug accumulation (eg, hematologic toxicity) is important. Due to minimal data in pediatric patients receiving CRRT, consider monitoring serum concentrations if available.
Infants, Children, and Adolescents: IV, Oral: Based on adult data, dosage adjustment is not necessary; monitor closely (Ref). Note: While pediatric data are lacking, high variability of linezolid pharmacokinetics has been observed in critically ill adult patients and those on renal replacement therapies; monitor patient closely for efficacy and toxicities, and utilize therapeutic drug monitoring when possible (Ref).
Mild to moderate impairment: No adjustment necessary.
Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Based on experience in adult patients, linezolid concentrations and risk of thrombocytopenia may be increased in patients with cirrhosis; use with caution and monitor closely; consider therapeutic drug monitoring when feasible (Ref).
(For additional information see "Linezolid: Drug information")
Dosage guidance:
Safety: Linezolid is not a preferred agent for the treatment of infections requiring prolonged therapy as the risk of serious hematologic and neurologic toxicity increases after >2 weeks and >4 weeks of therapy, respectively.
Anthrax, systemic infection (off-label use): Note: Consult public health officials for event-specific recommendations.
IV: 600 mg every 12 hours as part of an appropriate combination regimen. The duration for non-CNS infection is ≥2 weeks or until clinically stable, whichever is longer. The duration for meningitis is ≥2 to 3 weeks or until clinically stable, whichever is longer (Ref).
Note: Antitoxin should also be administered. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy with an appropriate agent to complete a total antimicrobial course of 60 days (Ref).
Bloodstream infection:
Empiric therapy or pathogen-directed therapy for methicillin-resistant Staphylococcus aureus (MRSA) (alternative agent) (off-label use): Oral, IV: 600 mg every 12 hours (Ref); treat uncomplicated S. aureus bacteremia for ≥14 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (Ref).
Empiric therapy or pathogen-directed therapy for vancomycin-resistant enterococci: Oral, IV: 600 mg every 12 hours; treat uncomplicated bacteremia for 7 to 14 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (Ref). Some experts recommend a duration of 5 to 7 days for uncomplicated infection with rapid blood culture clearance (within 24 hours) and in the absence of metastatic infection (Ref).
CNS infection, health care–associated (eg, cerebrospinal fluid shunt infection) (alternative agent) (off-label use): Pathogen-directed therapy for Staphylococcus spp., including methicillin-resistant species or Cutibacterium acnes.
Oral, IV: 600 mg every 12 hours; duration of therapy is generally 10 to 14 days (Ref). For staphylococci, usually used in combination with rifampin (eg, in the setting of retained hardware) (Ref), but conflicting data are available on the effect of rifampin on linezolid levels (Ref).
Diabetic foot infection, moderate to severe: Empiric therapy or pathogen-directed therapy for MRSA.
Oral, IV: 600 mg every 12 hours; for empiric therapy, use as part of an appropriate combination regimen. Duration is usually 2 to 4 weeks in the absence of osteomyelitis; prolonged use of linezolid may be limited by toxicity (Ref).
Endocarditis, treatment (off-label use):
Enterococcus, penicillin-, aminoglycoside-, and vancomycin-resistant:
IV, Oral: 600 mg every 12 hours for >6 weeks; prolonged use of linezolid may be limited by toxicity (Ref).
S. aureus, methicillin-resistant or penicillin-allergy for methicillin-susceptible, oral step-down therapy in patients who inject drugs:
Note: Not first-line therapy; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for methicillin-resistant S. aureus or penicillin allergy for methicillin-susceptible S. aureus but cannot complete IV standard of care therapy (Ref).
Oral: 600 mg every 12 hours in combination with rifampin for a total duration, including initial IV therapy, of 6 weeks (Ref).
Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess (alternative agent) (off-label use): Empiric or pathogen-directed therapy of MRSA.
IV, Oral: 600 mg every 12 hours; when used for empiric therapy, use as part of an appropriate combination regimen. Duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess, and 6 to 8 weeks for intracranial epidural abscess; prolonged use of linezolid may be limited by toxicity (Ref).
Meningitis, bacterial (off-label use): As pathogen-directed therapy (eg, penicillin-, ampicillin-, and vancomycin-resistant enterococci; Staphylococcus spp., including MRSA [alternative agent]; C. acnes [alternative agent]).
IV: 600 mg every 12 hours. Treatment duration is usually 10 to 14 days (Ref).
Osteomyelitis and/or discitis (alternative agent) (off-label use):
Pathogen-directed therapy for Staphylococcus spp., including MRSA: Oral, IV: 600 mg every 12 hours (Ref). Some experts combine with rifampin in the presence of retained hardware (Ref), but conflicting data are available on the effect of rifampin on linezolid levels (Ref).
Pathogen-directed therapy for Enterococcus spp.: Oral, IV: 600 mg every 12 hours (Ref).
Duration of therapy: Duration is generally ≥6 weeks; prolonged use of linezolid may be limited by toxicity. Shorter courses are appropriate if the affected bone is completely resected (eg, by amputation) (Ref).
Pneumonia, as a component of empiric therapy or pathogen-directed therapy for methicillin-resistant S. aureus:
Oral, IV: 600 mg every 12 hours; duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days. When used for empiric therapy, give as part of an appropriate combination regimen (Ref).
Prosthetic joint infection (alternative agent) (off-label use):
Pathogen-directed therapy for Enterococcus spp. (penicillin-susceptible or penicillin-resistant): Oral, IV: 600 mg every 12 hours for 4 to 6 weeks; prolonged use of linezolid may be limited by toxicity (Ref).
Pathogen-directed therapy for Staphylococcus spp., including MRSA: Oral, IV: 600 mg every 12 hours. Duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors; prolonged use of linezolid may be limited by toxicity (Ref).
Note: In select cases (eg, debridement and retention of prosthesis or one-stage arthroplasty), give oral suppressive antibiotic therapy with an appropriate regimen following completion of initial treatment (Ref).
Septic arthritis (alternative agent) (off-label use): Pathogen-directed therapy for MRSA.
Oral, IV: 600 mg every 12 hours. Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis); prolonged use of linezolid may be limited by toxicity (Ref). Some experts recommend 4 weeks of therapy for patients with concomitant bacteremia (Ref).
Skin and soft tissue infection (alternative agent): Empiric therapy or pathogen-directed therapy for resistant gram-positive organisms (eg, MRSA).
Oral, IV: 600 mg every 12 hours. Total duration of therapy is usually 5 to 14 days; for necrotizing infection, continue until further debridement is not necessary and the patient has improved clinically, including being afebrile for ≥48 hours (Ref). Note: For empiric therapy, give as part of an appropriate combination regimen (Ref).
Toxic shock syndrome (alternative agent) (off-label use):
Toxin production suppression due to group A streptococci: Oral, IV: 600 mg every 12 hours as part of an appropriate combination regimen. Duration is until clinically and hemodynamically stable for ≥48 to 72 hours; then discontinue linezolid and give monotherapy with an appropriate antistreptococcal agent (Ref).
Empiric therapy or pathogen-directed therapy for S. aureus, including MRSA and toxin production suppression: Oral, IV: 600 mg every 12 hours. Duration for toxin production is until clinically and hemodynamically stable for ≥48 to 72 hours; then discontinue linezolid and give monotherapy with an appropriate antistaphylococcal agent. If linezolid is given alone to complete therapy, the duration is typically 10 to 14 days in the absence of bacteremia (Ref).
Tuberculosis disease, drug-resistant (off-label use): Oral, IV: 600 mg once daily as part of an appropriate combination regimen including pyridoxine (Ref); dose reduction to 300 mg once daily or 600 mg 3 to 4 times weekly may be used for certain regimens or for patients who develop toxicity (Ref). Consider serum monitoring to ensure therapeutic concentration (Ref). Note: For patients <50 kg, an initial dose of 450 mg once daily has been suggested (Ref).
Duration of therapy: Individualize based on rapidity of culture conversion, extent of disease, and patient-specific factors, including clinical response and toxicity (Ref).
Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms) (alternative agent): Note: Reserve for use as a component of empiric therapy or pathogen-directed therapy for resistant gram-positive pathogens (eg, vancomycin-resistant enterococci) (Ref).
Oral, IV: 600 mg every 12 hours; duration generally ranges from 7 to 10 days depending on clinical response (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS
Note: Observational studies suggest an increased incidence of thrombocytopenia in patients with kidney impairment (Ref). Use with caution; utilize therapeutic drug monitoring when available and limit duration of use when possible.
Note: Renally adjusted dose recommendations are based on doses of 600 mg every 12 hours.
Altered kidney function:
Oral, IV:
CrCl 40 to <130 mL/minute: No dosage adjustment necessary.
CrCl <40 mL/minute: No dosage adjustment necessary. Based on Monte Carlo simulations, in clinically stable patients with CrCl <30 mL/minute and an anticipated treatment course >10 days, some experts suggest reducing dose to 300 mg twice daily after 72 hours with therapeutic drug monitoring to reduce the risk of thrombocytopenia (Ref).
Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2):
Note: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).
IV: 450 mg every 8 hours. Utilize therapeutic drug monitoring when available (Ref).
Hemodialysis, intermittent (thrice weekly): Dialyzable, parent drug and metabolites (~30% to 57% removed via high-flux dialyzer (Ref).
Oral, IV: No dosage adjustment necessary; when scheduled doses fall on dialysis days, 1 of the twice-daily doses should be administered after the dialysis session (Ref). Based on Monte Carlo simulations, in clinically stable patients with CrCl <30 mL/minute and an anticipated treatment course >10 days, some experts suggest reducing dose to 300 mg twice daily after 72 hours with therapeutic drug monitoring to reduce the risk of thrombocytopenia (Ref). More frequent monitoring of CBC should be considered due to increased risk of myelosuppression (Ref).
Peritoneal dialysis: Likely to be dialyzable (low protein binding, small volume of distribution) (Ref):
Oral, IV: No dosage adjustment necessary (Ref).
Based on Monte Carlo simulations, in clinically stable patients with CrCl <30 mL/minute and an anticipated treatment course >10 days, some experts suggest reducing dose to 300 mg twice daily after 72 hours with therapeutic drug monitoring to reduce the risk of thrombocytopenia (Ref). More frequent monitoring of CBC should be considered due to increased risk of myelosuppression (Ref).
CRRT:
Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, hematological toxicity) due to drug accumulation is important.
Oral, IV: No dosage adjustment necessary (Ref).
Note: High variability of linezolid pharmacokinetics has been observed in critically ill patients (Ref) and those on renal replacement therapies (Ref). Standard dose may not be sufficient for bacterial infections with high MIC ≥2 mg/L. Consider an alternative agent or utilize higher doses informed by therapeutic drug monitoring in patients at risk of toxicity or treatment failure (Ref).
PIRRT (eg, sustained, low-efficiency diafiltration):
Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, hematologic toxicity) due to drug accumulation is important.
Oral, IV: No dosage adjustment necessary. One of the twice-daily doses should be administered after PIRRT (Ref).
Note: High variability of linezolid pharmacokinetics has been observed in critically ill patients (Ref) and those on renal replacement therapies (Ref). Standard dose may not be sufficient for bacterial infections with MIC ≥2 mg/L; consider an alternative agent or utilize higher doses informed by therapeutic drug monitoring in patients at risk of toxicity or treatment failure (Ref).
Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.
Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling. Linezolid concentrations may be increased in patients with cirrhosis and risk of thrombocytopenia may be increased. Use with caution and monitor for thrombocytopenia; consider therapeutic drug monitoring when feasible (Ref).
Clostridioides difficile infection has occurred, including Clostridioides-difficile associated diarrhea and Clostridioides difficile colitis.
Onset: Varied; may start on the first day of antibiotic therapy or up to 3 months post-antibiotic (Ref).
Risk factors:
• Antibiotic exposure (highest risk factor) (Ref)
• Type of antibiotic (Ref); linezolid may pose significantly less risk (Ref)
• Long durations in a hospitalization or other health care setting (recent or current) (Ref)
• Older adults (Ref)
• Immunocompromised conditions (Ref)
• A serious underlying condition (Ref)
• GI surgery/manipulation (Ref)
• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (Ref)
• Chemotherapy (Ref)
Lactic acidosis has been reported with the use of linezolid. Patients who develop recurrent nausea and vomiting, unexplained acidosis, or low bicarbonate levels need immediate evaluation. Overall incidence is relatively low but can be life-threatening (Ref) with one study reporting an overall 6.8% incidence (Ref). Peak lactate levels ranged between 3 and 38 mmol/L (Ref). Most reports have occurred in adults; however, there are also reports in pediatric patients (Ref). Lactic acidosis is generally reversible within 15 days of discontinuation of linezolid; however, some cases may take longer to resolve or result in death (Ref).
Mechanism: Unclear; proposed mechanism is through inhibition of mitochondrial protein synthesis resulting in limited aerobic energy production. This leads to anaerobic glycolysis and lactate generation (Ref).
Onset: Varied; may occur on first day of therapy up to 109 days on therapy (Ref)
Risk factors:
• Age ≥60 years (Ref)
• Prolonged use (≥28 days) (Ref)
• Cmin (trough) >2 mg/L when given for an extended duration (Ref)
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) have been reported with the use of linezolid (Ref). Thrombocytopenia is the most frequently observed blood dyscrasia and has been reported more often in patients with severe kidney impairment and in patients with moderate to severe hepatic impairment. Myelosuppression is typically reversible with discontinuation of therapy (Ref) and typically takes 1 to 2 weeks to recover (Ref).
Mechanism: Unclear; proposed mechanism for linezolid-induced thrombocytopenia may be immune-mediated platelet destruction and for linezolid-induced anemia is likely due to direct bone marrow suppression via inhibition of mitochondrial respiration (Ref).
Onset: Intermediate; typically occurs ≥14 days of therapy (Ref); although some studies have noted thrombocytopenia occurring within 7 days of therapy initiation (Ref).
Risk factors:
• Prolonged use (≥14 days) (Ref)
• Baseline platelet count ≤200 x 109/L (Ref)
• Higher daily per kg dose (Ref)
• Cmin (trough) >2 mg/L when given for an extended duration (Ref)
• Preexisting myelosuppression
• Severe kidney impairment or moderate to severe hepatic impairment
• Concurrent medications that cause bone marrow suppression
• Chronic infection (previous or concurrent antibiotic therapy)
Peripheral neuropathy and optic neuropathy have been reported in both adults and pediatric patients. Symptoms reported related to peripheral neuropathy include pain, numbness, paresthesia, and weakness (Ref). Symptoms related to optic neuropathy include decreased visual acuity, color vision, and sensation of brightness (Ref). Improvement or complete recovery of optic neuropathy typically occurs with discontinuation of therapy; however, complete recovery of peripheral neuropathy may not occur with discontinuation of therapy (Ref).
Mechanism: Unclear; may be associated with mitochondrial toxicity (Ref).
Onset: Intermediate; typically occurs ≥28 days of therapy (Ref); although, there have been some reports of cases occurring before 28 days of therapy (Ref).
Risk factors:
• Prolonged use (≥28 days) (Ref)
• Cmin (trough) >2 mg/L when given for an extended duration (Ref)
Symptoms of agitation, confusion, hallucinations, hyperreflexia, myoclonus, shivering, and tachycardia may occur. Typically reversible within 48 hours of discontinuation of linezolid and/or serotonergic agents (Ref); however, some reported cases have resulted in death (Ref).
Mechanism: Non–dose-related; reversible, weak nonselective monoamine oxidase inhibitor, resulting in inhibition of serotonin metabolism (Ref).
Onset: Intermediate; range from 1 to 20 days, median of 4 days (Ref)
Risk factors:
• Concurrent use with serotonergic agents (eg, selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors) (Ref)
• Concurrent use with agents which reduce linezolid metabolism
• Carcinoid syndrome
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%:
Gastrointestinal: Diarrhea (8% to 11%)
Hematologic & oncologic: Decreased white blood cell count (neonates, infants, and children: 12%; children, adolescents, and adults: ≤2%)
1% to 10%:
Dermatologic: Pruritus (neonates, infants, children, and adolescents: ≤1%; nonapplication site), skin rash (adults: 1% to 2%)
Endocrine & metabolic: Increased lactate dehydrogenase (adults: ≤2%)
Gastrointestinal: Abdominal pain (≤2%), dysgeusia (adults: 1% to 2%), increased serum amylase (neonates, infants, children, and adults: ≤2%), increased serum lipase (adults: 3% to 4%; children and adolescents: <1%), loose stools (neonates, infants, children, and adolescents: 2%), nausea (2% to 7%), oral candidiasis (adults: ≤2%), tongue discoloration (adults: ≤1%), vomiting (2% to 9%)
Genitourinary: Vulvovaginal candidiasis (adults: 1% to 2%)
Hematologic & oncologic: Anemia (neonates, infants, and children: 6%; adults ≤2%) (table 1) , decreased neutrophils (neonates, infants, and children: 6%; children, adolescents, and adults: ≤1%), decreased platelet count (adults: ≤10%) (table 2) , eosinophilia (neonates, infants, children, and adolescents: ≤2%), thrombocytopenia (neonates, infants, and children: 5%) (table 3)
Drug (Linezolid) |
Comparator |
Population |
Dose |
Dosage Form |
Indication |
Number of Patients (Linezolid) |
Number of Patients (Comparator) |
Comments |
---|---|---|---|---|---|---|---|---|
6% |
7% |
Neonates, infants, and children |
10 mg/kg every 8 hours |
Oral or IV |
N/A |
215 |
101 |
Comparator: Vancomycin |
0% |
0% |
Children and adolescents |
Patients 5 through 11 years of age: 10 mg/kg every 12 hours; patients 12 years or older: 600 mg every 12 hours |
Oral |
Uncomplicated skin and skin structure infections |
248 |
251 |
Comparator: Cefadroxil |
2% |
1% |
Adults |
600 mg every 12 hours |
N/A |
N/A |
1,498 |
1,464 |
Comparator: Cefpodoxime proxetil, ceftriaxone, dicloxacillin, oxacillin, or vancomycin |
0.4% |
0% |
Adults |
400 mg every 12 hours |
Oral |
Uncomplicated skin and skin structure infections |
548 |
537 |
Comparator: Clarithromycin |
Drug (Linezolid) |
Comparator |
Population |
---|---|---|
0.3% to 10% |
0.4% to 7% |
Adults |
Drug (Linezolid) |
Comparator |
Population |
Dose |
Dosage Form |
Indication |
Number of Patients (Linezolid) |
Number of Patients (Comparator) |
Comments |
---|---|---|---|---|---|---|---|---|
5% |
2% |
Neonates, infants, and children |
10 mg/kg every 8 hours |
Oral or IV |
N/A |
215 |
101 |
Comparator: Vancomycin |
0% |
0% |
Children and adolescents |
Patients 5 through 11 years of age: 10 mg/kg every 12 hours; patients 12 years or older: 600 mg every 12 hours |
Oral |
Uncomplicated skin and skin structure infections |
248 |
251 |
Comparator: Cefadroxil |
Hepatic: Abnormal hepatic function tests (adults: ≤2%), increased serum alanine aminotransferase (neonates, infants, children, and adults: 2% to 10%), increased serum alkaline phosphatase (adults: ≤4%), increased serum aspartate aminotransferase (adults: 2% to 5%), increased serum bilirubin (neonates, infants, and children: 6%; adults: <1%)
Infection: Fungal infection (adults: ≤2%)
Nervous system: Dizziness (adults: 2% to 3%), headache (children, adolescents, and adults: 6% to 9%; neonates, infants, and children: <1%), vertigo (children and adolescents: 1%)
Renal: Increased blood urea nitrogen (adults: ≤2%), increased serum creatinine (≤2%)
Postmarketing:
Dermatologic: Bullous skin disease (Chen 2020), Stevens-Johnson syndrome, toxic epidermal necrolysis (Ivic 2014)
Endocrine & metabolic: Hypoglycemia (Johannesmeyer 2017), hyponatremia (Ioannou 2018), lactic acidosis (Im 2015, Mao 2018), SIADH (Baik 2015)
Gastrointestinal: Clostridioides difficile-associated diarrhea, hematemesis (Chitsulo 2023), melanoglossia (Braggio 2018), staining of tooth (Santos 2015)
Hematologic & oncologic: Leukopenia (Bayram 2017), pancytopenia (Leader 2018), pure red cell aplasia (Yang 2022), sideroblastic anemia (Willekens 2013)
Hypersensitivity: Anaphylaxis, angioedema (Yang 2012), hypersensitivity angiitis (Kruzer 2018)
Nervous system: Hallucination (Maqsood 2022), peripheral neuropathy (Vishnu 2016), psychosis (Maqsood 2022), seizure (Cholongitas 2009, Shneker 2009), serotonin syndrome (Karkow 2017)
Ophthalmic: Blurred vision (Lee 2003), optic neuropathy (Lee 2018), vision loss (Lee 2003)
Hypersensitivity to linezolid or any component of the formulation; concurrent use or within 2 weeks of MAO inhibitors.
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Canadian labeling: Additional contraindications (not in US labeling): Unless monitored for potential increases in blood pressure, linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following: sympathomimetic agents (eg, pseudoephedrine, phenylpropanolamine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine). Unless carefully observed for signs and/or symptoms of serotonin syndrome, linezolid should not be administered to patients with carcinoid syndrome and/or patients taking any of the following: SSRIs; TCAs; serotonin 5-HT1 receptor agonists (triptans); opioids, including meperidine; or buspirone.
Concerns related to adverse effects:
• Superinfection: Prolonged use may result in fungal or bacterial superinfection.
Disease-related concerns:
• Carcinoid syndrome: Use with caution and closely monitor for serotonin syndrome in patients with carcinoid syndrome.
• Hepatic impairment: Use with caution in patients with liver cirrhosis; risk of thrombocytopenia may be increased (Luque 2019; Sasaki 2011).
• Hypertension: Use with caution and closely monitor BP in patients with uncontrolled hypertension.
• Hyperthyroidism: Use with caution and closely monitor BP in patients with untreated hyperthyroidism.
• Pheochromocytoma: Use with caution and closely monitor BP in patients with pheochromocytoma.
• Renal impairment: Use with caution; risk of thrombocytopenia may be increased (Hanai 2016).
• Seizure disorder: Seizures have been reported; use with caution in patients with a history of seizures.
Dosage form specific issues:
• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.
• Phenylalanine: Some products may contain phenylalanine.
Other warnings/precautions:
• Appropriate use: Unnecessary use may lead to the development of resistance to linezolid; consider alternatives before initiating outpatient treatment.
• Catheter-related bloodstream infections (CRBSI): Linezolid should not be used in the empiric treatment of CRBSI but may be appropriate for targeted therapy (Mermel 2009).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Intravenous:
Generic: 600 mg/300 mL (300 mL)
Solution, Intravenous [preservative free]:
Zyvox: 200 mg/100 mL (100 mL); 600 mg/300 mL (300 mL)
Generic: 600 mg/300 mL (300 mL)
Suspension Reconstituted, Oral:
Zyvox: 100 mg/5 mL (150 mL) [contains aspartame, sodium benzoate]
Zyvox: 100 mg/5 mL (150 mL [DSC]) [contains aspartame, sodium benzoate; orange flavor]
Generic: 100 mg/5 mL (150 mL)
Tablet, Oral:
Zyvox: 600 mg
Generic: 600 mg
Yes
Solution (Linezolid in Sodium Chloride Intravenous)
600MG/300ML 0.9% (per mL): $0.28
Solution (Linezolid Intravenous)
600MG/300ML (per mL): $0.05 - $0.37
Solution (Zyvox Intravenous)
200 mg/100 mL (per mL): $0.69
600MG/300ML (per mL): $0.13
Suspension (reconstituted) (Linezolid Oral)
100 mg/5 mL (per mL): $2.69 - $6.38
Suspension (reconstituted) (Zyvox Oral)
100 mg/5 mL (per mL): $5.46
Tablets (Linezolid Oral)
600 mg (per each): $181.83 - $288.00
Tablets (Zyvox Oral)
600 mg (per each): $325.21
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Intravenous:
Zyvoxam: 600 mg/300 mL (300 mL)
Generic: 600 mg/300 mL (300 mL)
Suspension Reconstituted, Oral:
Zyvoxam: 100 mg/5 mL (150 mL) [contains aspartame, sodium benzoate]
Tablet, Oral:
Zyvoxam: 600 mg [DSC] [contains alcohol, usp]
Generic: 600 mg
Oral: Administer with or without food. With reconstituted suspension, gently invert bottle 3 to 5 times before use. Do not shake.
Parenteral: IV: Check infusion bag for minute leaks and solution for particulate matter prior to administration. Administer without further dilution over 30 to 120 minutes. When the same intravenous line is used for sequential infusion of other medications, flush line with D5W, NS, or LR before and after infusing linezolid. The yellow color of the injection may intensify over time without affecting potency.
IV: Administer intravenous infusion over 30 to 120 minutes. When the same intravenous line is used for sequential infusion of other medications, flush line with D5W, NS, or LR before and after infusing linezolid. The yellow color of the injection may intensify over time without affecting potency.
Oral: Administer without regard to meals.
Oral suspension: Invert gently to mix prior to administration, do not shake.
Infusion: Store at 25°C (77°F). Protect from light and freezing. Keep infusion bags in overwrap until ready for use.
Oral suspension: Store at 25°C (77°F); following reconstitution store at room temperature and use suspension within 21 days. Protect from light.
Tablet: Store at 25°C (77°F). Protect from light and moisture.
Treatment of community-acquired pneumonia, nosocomial pneumonia (eg, hospital-acquired, ventilator-associated), uncomplicated and complicated skin and soft tissue infections, and vancomycin-resistant Enterococcus faecium infections (All indications: FDA approved in all ages). Has also been used for the treatment of bloodstream infections, osteoarticular infections, meningitis, tuberculosis, Mycobacterium abscessus pulmonary infections, and exit-site or tunnel infections and peritonitis in patients with peritoneal dialysis catheters.
Zyvox may be confused with Zosyn, Zovirax
Substrate of CYP2J2 (minor), CYP4F2 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits Monoamine Oxidase
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy
Agents with Blood Glucose Lowering Effects: Monoamine Oxidase Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Alcohol (Ethyl): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Risk C: Monitor therapy
Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Amphetamines: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details. Risk X: Avoid combination
Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor therapy
Apraclonidine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine. Risk X: Avoid combination
ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Atomoxetine: Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of Atomoxetine. Risk X: Avoid combination
Atropine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Atropine (Ophthalmic). Risk X: Avoid combination
Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination
BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy
Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Benzhydrocodone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and frequent titration of small benzhydrocodone. Risk D: Consider therapy modification
Betahistine: Monoamine Oxidase Inhibitors may increase the serum concentration of Betahistine. Risk C: Monitor therapy
Bezafibrate: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Risk X: Avoid combination
Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Brimonidine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Ophthalmic). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Ophthalmic). Risk C: Monitor therapy
Brimonidine (Topical): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Topical). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Topical). Risk C: Monitor therapy
Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Buprenorphine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
BuPROPion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of BuPROPion. Risk X: Avoid combination
BusPIRone: May enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. Risk X: Avoid combination
Butorphanol: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
CarBAMazepine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Do not use carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor. Risk X: Avoid combination
Carbinoxamine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Carbinoxamine. Specifically, the anticholinergic effects of carbinoxamine may be enhanced and prolonged. Risk X: Avoid combination
Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Cerebrolysin: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk C: Monitor therapy
Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy
Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). Risk X: Avoid combination
Chlorphenesin Carbamate: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk C: Monitor therapy
ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination
Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk X: Avoid combination
Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy
CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Codeine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Codeine. Risk X: Avoid combination
COMT Inhibitors: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Avoid coadministration of COMT inhibitors and nonselective monoamine oxidase inhibitors (MAOIs) (eg, isocarboxazid, phenelzine, tranylcypromine, linezolid, methylene blue) whenever possible. Risk D: Consider therapy modification
Cyclobenzaprine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
CycloSPORINE (Systemic): May increase the serum concentration of Linezolid. Risk C: Monitor therapy
Cyproheptadine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated. Risk X: Avoid combination
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider therapy modification
Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. Risk X: Avoid combination
Dexmethylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Dexmethylphenidate. Risk X: Avoid combination
Dextromethorphan: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This may cause serotonin syndrome. Risk X: Avoid combination
Diamorphine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Diamorphine. Risk X: Avoid combination
Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. Risk X: Avoid combination
Dihydrocodeine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Consider avoiding use of dihydrocodeine while the patient is taking monoamine oxidase inhibitors (MAOIs) and for 2 weeks after MAOI discontinuation. Risk D: Consider therapy modification
Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination
Domperidone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. Risk C: Monitor therapy
DOPamine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of DOPamine. Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine. Risk D: Consider therapy modification
DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Droxidopa: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Droxidopa. Risk X: Avoid combination
EPINEPHrine (Oral Inhalation): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). Risk X: Avoid combination
Epinephrine (Racemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Epinephrine (Racemic). Risk C: Monitor therapy
Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Esketamine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk C: Monitor therapy
Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination
Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination
Fenfluramine: May enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. Risk X: Avoid combination
Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. Risk X: Avoid combination
Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Gepirone: May enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. Risk X: Avoid combination
Guanethidine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
HYDROcodone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROcodone. HYDROcodone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Consider alternatives to this combination when possible. If coadministration is required, use test doses, titrate small doses frequently, and monitor patients closely for evidence of serotonergic and opioid toxicities. Risk D: Consider therapy modification
HYDROmorphone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROmorphone. Management: Coadministration of hydromorphone and monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) is not recommended. If required, use test doses, titrate small doses frequently, and monitor for CNS and respitatory depression. Risk D: Consider therapy modification
Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy
Indoramin: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Indoramin. Risk X: Avoid combination
Iobenguane Radiopharmaceutical Products: Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Risk X: Avoid combination
Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider therapy modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider therapy modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider therapy modification
Isometheptene: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Isometheptene. Risk X: Avoid combination
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy
Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Levodopa-Foslevodopa: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI. Risk X: Avoid combination
Levomethadone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Levonordefrin: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Levonordefrin. Risk X: Avoid combination
Lithium: Linezolid may enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes). Risk D: Consider therapy modification
Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Maprotiline: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Meptazinol: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Meptazinol. Risk X: Avoid combination
Mequitazine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Mequitazine. Risk X: Avoid combination
Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Methadone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
Methotrimeprazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, monoamine oxidase inhibitors may enhance dopamine blockade, possible increasing the risk for neuroleptic malignant syndrome. Methotrimeprazine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
Methyldopa: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methyldopa. Risk X: Avoid combination
Methylene Blue: May enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. Risk X: Avoid combination
Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. Risk X: Avoid combination
Metoclopramide: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. Risk X: Avoid combination
Mivacurium: Monoamine Oxidase Inhibitors may increase the serum concentration of Mivacurium. Risk C: Monitor therapy
Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Monoamine Oxidase Inhibitors (Antidepressant): Linezolid may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. Risk X: Avoid combination
Monoamine Oxidase Inhibitors (Type B): Linezolid may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome. Risk X: Avoid combination
Morphine (Systemic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Morphine (Systemic). Risk X: Avoid combination
Nalbuphine: Monoamine Oxidase Inhibitors may enhance the CNS depressant effect of Nalbuphine. Nalbuphine may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Nalbuphine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Use of nalbuphine is not recommended in patients taking MAOIs, or within 14 days of stopping MAOI therapy. If urgent nalbuphine use is needed, use test doses and frequent titration while monitoring blood pressure, CNS depression, and serotonergic toxicity Risk D: Consider therapy modification
Nefazodone: Linezolid may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Risk X: Avoid combination
Nefopam: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Nefopam. Risk X: Avoid combination
Normethadone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Normethadone. Risk X: Avoid combination
OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. Risk C: Monitor therapy
Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Opicapone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Opioid Agonists: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Opium: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Opium. Risk X: Avoid combination
Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
OxyCODONE: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Use of oxycodone is not recommended for patients taking MAOIs or within 14 days of MAOI discontinuation. If combined, use test doses and frequent titration of small doses while monitoring blood pressure, CNS depression, and signs of serotonin syndrome. Risk D: Consider therapy modification
OxyMORphone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Ozanimod: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Pheniramine: May enhance the anticholinergic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Pholcodine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Pizotifen: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. Risk X: Avoid combination
Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor therapy
Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy
Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Reboxetine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reboxetine. Risk X: Avoid combination
Remifentanil: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Remifentanil. Specifically, the risk for opioid toxicity (eg, respiratory depression) may be increased. Remifentanil may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: The use of remifentanil is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and titrate small doses of remifentanil frequently. Risk D: Consider therapy modification
Reserpine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension). Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine. Monitor closely for paradoxical effects of reserpine (eg, excitation, hypertension). Risk D: Consider therapy modification
RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider therapy modification
Selective Serotonin Reuptake Inhibitors: Linezolid may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
Serotonergic Non-Opioid CNS Depressants: Linezolid may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Risk X: Avoid combination
Serotonergic Opioids (High Risk): Linezolid may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes). Risk D: Consider therapy modification
Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans). Risk X: Avoid combination
Serotonin/Norepinephrine Reuptake Inhibitors: Linezolid may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Sevoflurane: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Sevoflurane. Specifically, the risk of hemodynamic instability may be increased. Risk C: Monitor therapy
Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification
Solriamfetol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Solriamfetol. Risk X: Avoid combination
St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
SUFentanil: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression. Risk X: Avoid combination
Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Sympathomimetics: Linezolid may enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider therapy modification
Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy
Tapentadol: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the additive effects of norepinephrine may lead to adverse cardiovascular effects. Tapentadol may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination
Tetrabenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Tetrahydrozoline (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal). Risk X: Avoid combination
Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Tianeptine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Tricyclic Antidepressants: Linezolid may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Risk X: Avoid combination
Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Tryptophan: Linezolid may enhance the serotonergic effect of Tryptophan. This could result in serotonin syndrome. Risk X: Avoid combination
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification
Tyrosine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Valbenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Viloxazine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination
Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy
Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Beverages containing tyramine (eg, hearty red wine and beer) may increase toxic effects. Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food’s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine. Avoid beverages containing tyramine.
Some products may contain sodium and/or phenylalanine. Avoid consuming large amounts of tyramine-containing foods/beverages. Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salami), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments.
Information related to linezolid use during pregnancy is limited (Jaspard 2017; Mercieri 2010). Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of linezolid may be altered (van Kampenhout 2017).
Weekly CBC, particularly in the following patients: Patients at increased risk for bleeding, patients with preexisting myelosuppression, patients receiving concomitant medications that cause bone marrow suppression, patients receiving >2 weeks of therapy, patients with chronic infection who have received previous or concomitant antibiotic therapy; more frequent monitoring may be warranted in certain scenarios based on clinical judgment (Jones 2015; Norris 2019; manufacturer's labeling). Weekly liver function tests with extended use (Norris 2019). Sodium (routinely in patients at risk of hyponatremia [eg, patients receiving diuretics] and/or syndrome of inappropriate antidiuretic hormone secretion [SIADH]). Periodic serum bicarbonate with extended therapy. Consider monitoring lactate in patients with renal or hepatic dysfunction or who are receiving long-term therapy (Su 2011).
Peripheral sensory and visual function with extended therapy (eg, ≥3 months) or in patients with new-onset neuropathic or visual symptoms, regardless of therapy length (any symptoms of visual change or impairment warrant immediate ophthalmic evaluation) (Nambiar 2011; manufacturer's labeling). Monitor for signs and symptoms of lactic acidosis (eg, recurrent nausea and vomiting, unexplained acidosis, low bicarbonate levels) and signs and symptoms of hyponatremia. Monitor for signs and symptoms of serotonin syndrome or neuroleptic malignant syndrome-like reaction (especially in patients on concomitant serotonergic agents). Monitor for diarrhea.
Linezolid concentration monitoring is not routine, but may be considered in certain scenarios (eg, pathogens with minimum inhibitory concentrations [MICs] ≥2 mg/L, kidney impairment, drug-drug interactions, inadequate response to infection, patients at increased risk for adverse effects) (Cojutti 2015; Li 2019; Rao 2020; Thibault 2019).
Gram-positive bacterial infections: Efficacy targets:
AUC24/MIC: ≥80 to 120 (Li 2019; Rao 2020).
Trough concentration: 2 to 7 mg/L (Cojutti 2015; Rao 2020).
Toxicity:
Hematological toxicity may be associated with Cmin (trough) >7 to 10 mg/L (Abdul-Aziz 2020; Cattaneo 2013; Kawasuji 2021; Pea 2012) or AUC >280 to 350 mg•hour/L (Abdul-Aziz 2020; Pea 2012).
Mitochondrial toxicity (peripheral neuropathy, optic neuropathy, lactic acidosis, myelosuppression) may be associated with Cmin (trough) >2 mg/L when given for an extended duration (Song 2015).
Inhibits bacterial protein synthesis by binding to bacterial 23S ribosomal RNA of the 50S subunit. This prevents the formation of a functional 70S initiation complex that is essential for the bacterial translation process. Linezolid is bacteriostatic against enterococci and staphylococci and bactericidal against most strains of streptococci.
Absorption: Rapid and extensive.
Distribution:
Vd:
Neonates, GA <34 weeks:
PNA <7 days: 0.81 L/kg.
PNA >7 days: Median 0.99 L/kg; range: 0.7 to 1.45 L/kg (Thibault 2019).
Neonates, GA ≥34 weeks:
PNA <7 days: 0.78 L/kg.
PNA 7 to ≤28 days: 0.66 L/kg.
Infants <3 months of age: 0.79 L/kg.
Infants ≥3 months and Children ≤11 years of age: 0.69 L/kg.
Children ≥12 years and Adolescents: 0.61 L/kg.
Adults: 0.65 L/kg.
Bone (cancellous):serum ratio, steady state, mean: 40% (range: 16% to 53%) (Rana 2002).
CSF:blood ratio: ~60% to 70% (Myrianthefs 2006; Tsona 2010).
Lung penetration:
Epithelial lining fluid:serum ratio, steady state: ≥100%; varies with time (Boselli 2005; Boselli 2012; Conte 2002; Honeybourne 2003).
Tissue:serum ratio, steady state: ~49% (range: 17% to 132%) (Kempker 2018).
Protein binding: Adults: 31%.
Metabolism: Hepatic via oxidation of the morpholine ring, resulting in two inactive metabolites (aminoethoxyacetic acid, hydroxyethyl glycine); minimally metabolized, may be mediated by cytochrome P450.
Bioavailability: Oral: ~100%.
Half-life elimination:
Neonates, GA <34 weeks:
PNA <7 days: 5.6 hours.
PNA >7 days: Median: 3.44 hours; range: 2.44 to 9.77 hours (Thibault 2019).
Neonates, GA ≥ 34 weeks:
PNA <7 days: 3 hours.
PNA 7 to ≤28 days: 1.5 hours.
Infants <3 months of age: 1.8 hours.
Infants ≥3 months and Children ≤11 years of age: 2.9 hours.
Children ≥12 years and Adolescents: 4.1 hours.
Adults: 4.9 hours.
Time to peak: Adults: Oral: 1 to 2 hours.
Excretion: Urine (~30% of total dose as parent drug, ~50% of total dose as metabolites); two metabolites of linezolid may accumulate in patients with severe renal impairment; feces (~9% of total dose as metabolites).
Nonrenal clearance: Adults: ~65%.
Clearance:
Neonates, GA <34 weeks:
PNA <7 days: 2 mL/minute/kg.
PNA >7 days: Median ~2.8 mL/minute/kg; range: ~1.2 to 5.2 mL/minute/kg (Thibault 2019).
Neonates, GA ≥ 34 weeks:
PNA <7 days: 3.8 mL/minute/kg.
PNA 7 to ≤28 days of age: 5.1 mL/minute/kg.
Infants <3 months of age: 5.4 mL/minute/kg.
Infants ≥3 months and Children ≤11 years of age: 3.8 mL/minute/kg.
Children ≥12 years and Adolescents: 2.1 mL/minute/kg.
Adults: 1.7 mL/minute/kg.
Altered kidney function: Data are conflicting regarding the contribution of renal dysfunction to the elimination of linezolid. Several studies indicate that linezolid exposure is increased in patients with significant renal dysfunction (Cattaneo 2016; Gervasoni 2015; Ide 2018; Matsumoto 2010; Nukui 2013; Sasaki 2011; Tsuji 2017) although this may be reduced by a compensatory increase in non-renal elimination (Brier 2003; El-Assal 2014). Metabolites A and B accumulate in patients with renal insufficiency; the significance of this accumulation is not known.
Anti-infective considerations:
Parameters associated with efficacy:
Gram-positive bacterial infection: AUC24/minimum inhibitory concentration (MIC), goal: ≥80 to 120; %T > MIC, goal: ≥ ~85% (Abdul-Aziz 2020; Rayner 2003); lower AUC targets may be appropriate for streptococcal infections and higher targets may be needed for bone infection (Andes 2002; Rayner 2003).
Mycobacterium tuberculosis: %T > MIC, goal: 100% (1-log kill, acute phase); %T > MIC, goal: 77% (1-log kill, chronic phase); AUC24/MIC, goal: 1,000 (1-log kill, chronic phase) (Bigelow 2020).
Expected drug exposure in patients with normal renal function:
Cmax (peak) serum concentrations:
600 mg once daily: ~13 mg/L (Kempker 2018).
600 mg twice daily: 18 to 23 mg/L, steady state (Boselli 2005; Myrianthefs 2006; Rana 2002; manufacturer's labeling).
AUC:
Children 2 to 11 years of age: AUC24: ~10 mg/kg 3 times daily: ~240 mg•hour/L (IQR 174 to 395) (Cojutti 2015).
Children 12 years of age and adolescents: AUC24: ~10 mg/kg twice daily: ~300 mg•hour/L (IQR 204 to 655) (Cojutti 2015).
Adults: AUC24: 600 mg twice daily: 154 to 276 mg•hour/L (Boselli 2005; manufacturer's labeling).
Postantibiotic effect:
Methicillin-susceptible S. aureus: ~1 to 3 hours; S. pneumoniae: None (Andes 2002; Chen 2018).
Parameters associated with toxicity:
Hematological toxicity: Cmin (trough) >7 to 10 mg/L (Abdul-Aziz 2020; Cattaneo 2013; Pea 2012); AUC >280 to 350 mg•hour/L (Abdul-Aziz 2020; Pea 2012).
Mitochondrial toxicity (peripheral neuropathy, optic neuropathy, lactic acidosis, myelosuppression): Cmin (trough) >2 mg/L when given for an extended duration (Song 2015).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟